Sultan Alshehri1, Afzal Hussain1, Mohd Neyaz Ahsan2, Raisuddin Ali1, Mohd Usman Mohd Siddique3. 1. Department of Pharmaceutics, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia. 2. Department of Medical Laboratory Technology University Polytechnic, Birla Institute of Technology, Mesra, Ranchi 835215, Jharkhand, India. 3. Department of Pharmaceutical Chemistry, Shri Vile Parley Kelavani Mandal's Institute of Pharmacy, Dhule 424001, Maharastra, India.
Abstract
The study aimed to select a suitable solvent capable to solubilize ketoconazole (KETO) and serve as a permeation enhancer across the skin. Experimental solubility and Hansen solubility parameters were obtained in ethanol, dimethyl sulfoxide (DMSO), ethylene glycol, oleic acid, span 80, limonene, eugenol, transcutol (THP), labrasol, and propylene glycol. Thermodynamic functional parameters and computational models (van't Hoff and Apelblat) validated the determined solubility in various solvents at T = 298.2 K to 318.2 K and P = 0.1 MPa. The HSPiP software estimated the solubility parameters in the solvents. The maximum mole fractional solubility values of KETO were found to be in an order as oleic acid (8.5 × 10-3) > limonene (7.3 × 10-3) > span 80 (6.9 × 10-2) > THP (4.9 × 10-2) > eugenol (4.5 × 10-3) at T = 318.2 K. The results of the apparent thermodynamic analysis confirmed that the dissolution rate was endothermic and entropy driven. The GastroPlus program predicted significantly high permeation of KETO (79.1%) in human skin from the KETO-THP construct as compared to drug solution (38%) and excellent immediate release from THP-solubilized construct (90% < 1 h). Hence, THP could be a better option for topical, transdermal, and oral formulation.
The study aimed to select a suitable solvent capable to solubilize ketoconazole (KETO) and serve as a permeation enhancer across the skin. Experimental solubility and Hansen solubility parameters were obtained in ethanol, dimethyl sulfoxide (DMSO), ethylene glycol, oleic acid, span 80, limonene, eugenol, transcutol (THP), labrasol, and propylene glycol. Thermodynamic functional parameters and computational models (van't Hoff and Apelblat) validated the determined solubility in various solvents at T = 298.2 K to 318.2 K and P = 0.1 MPa. The HSPiP software estimated the solubility parameters in the solvents. The maximum mole fractional solubility values of KETO were found to be in an order as oleic acid (8.5 × 10-3) > limonene (7.3 × 10-3) > span 80 (6.9 × 10-2) > THP (4.9 × 10-2) > eugenol (4.5 × 10-3) at T = 318.2 K. The results of the apparent thermodynamic analysis confirmed that the dissolution rate was endothermic and entropy driven. The GastroPlus program predicted significantly high permeation of KETO (79.1%) in human skin from the KETO-THP construct as compared to drug solution (38%) and excellent immediate release from THP-solubilized construct (90% < 1 h). Hence, THP could be a better option for topical, transdermal, and oral formulation.
The incidence of fungal infections occurred
about 40 million in
developing and under developing nations as per global estimates.[1] Chemically, ketoconazole (KETO) is an azole type
(±) (cis-1-acetyl-4-[4-[2-(2,4-dichlorophenyl-2-(1H-imidazol-1ylmethyl)-1,3-dioxalon-4-yl]methoxy]phenyl]piperazine)
antifungal drug for local and systemic treatments.[2] The empirical molecular formula and molecular weight of
KETO are C26H28Cl2N4O4 (Figure A)
and 531.43 g mol–1, respectively.[3] Azole molecules are the first choice option to treat cutaneous
and systemic fungal infections. However, the drug possesses poor aqueous
solubility (0.04 mg/mL at 25 °C), high partition coefficient
(logP = 4.31), and limited oral bioavailability.[3] The drug is reported to treat several cutaneous
fungal infections such as (a) onychomychosis (nail fungal infection),
(b) psoriasis, (c) dermatitis, and (d) fungal infections (Candida species and Cryptococcus neoformans) associated with other diseases (human immunodeficiency virus).[4] The poor aqueous solubility challenged the drug
for parenteral, oral, and topical delivery to treat these fungal infections.
A high oral dose owing to limited aqueous solubility results in dose-related
toxic side effects. Therefore, topical and transdermal delivery could
be a suitable alternative using a suitable permeation enhancer. Hossin
et al. investigated the nail–drug interaction (affinity) using
Hansen solubility parameters, which can assist formulation scientists
to design a suitable carrier or solvent selection (DMSO, N-methyl pyrrolidone, ethanol, and ethylene glycol) for topical application
with improved efficacy.[5] Hashemzadeh and
Jouyban studied the binary system of ethanol + water mixture for improved
solubility of KETO at various temperatures using a Jouyban–Acree
model of co-solvency.[2] Moreover, authors
reported that KETO exhibited the maximum mole fractional solubility
(0.117) at 308.2 K when the mass fraction of ethanol in water was
0.8.[2] They also reported KETO molar solubilities
of 1.40 × 10–5 and 2.90 × 10–5 at 293.2 and 308.2 K in water, respectively.[2] Jouyban et al. explored the solubility of KETO in various polyethylene
glycol-200 + water binary systems at various temperature range (298.2–318.32
K) wherein the computational models (Jouyban–Acree and vanʼt
Hoff models) were the best fit to the experimental solubility data
within acceptable range of mean relative deviation (MRD) values.[6] In further development, polyethylene glycols
(of various molecular weights such as 200, 400, and 600) were used
for the solubility study of KETO as binary as well as ternary with
ethanol or water at 298.2 K. Soltanpour and Nazemi investigated that
the binary mixture of ethanol + water showed relatively less molar
solubility (0.041–3.071) over explored mass fractions (0.1–0.9),
whereas the binary mixture of the PEG + water system exhibited higher
molar solubility (0.065–3.86 for PEG200, 0.04–9.87 for
PEG400, and 0.145–10.71 for PEG600) at the same mass fraction
and experimental temperature (298.2 K).[7] They also studied that the binary system of ethanol + PEG revealed
increased solubility with increase in the PEG molecular weight (PEG600
> PEG400 > PEG200).[7] Considering
these,
there are several safe and biocompatible permeation enhancers, which
may be explored for solubilizing KETO, which can assist enhanced permeation
across the stratum corneum (SC) after topical or transdermal application.
These are ethanol, propylene glycol, labrasol, transcutol, eugenol,
limonene, span 80, oleic acid, ethylene glycol, and DMSO (dimethyl
sulfoxide).[8] KETO (bearing two pKa values
such as 2.94 and 6.51) solubility in acetate buffer (pH = 5.0) was
reported to be 0.3 mg/mL, and the solubility was increased to 4.6
mg/mL by fabricating as KETO succinate co-crystals. KETO is a weakly
basic molecule.[9]
Figure 1
(A) Chemical structure
of ketoconazole, (B) DSC thermogram of pure
and equilibrated ketoconazole (recovered from methanol), and (C) chromatogram
of pure ketoconazole with a retention time of 6.789 min from method
validation (Empower 2 software)
(A) Chemical structure
of ketoconazole, (B) DSC thermogram of pure
and equilibrated ketoconazole (recovered from methanol), and (C) chromatogram
of pure ketoconazole with a retention time of 6.789 min from method
validation (Empower 2 software)No studies have been conducted for Hansen solubility, thermodynamic
parameters, computational validation, and the GastroPlus-based in silico prediction of ketoconazole for topical or transdermal
delivery employing these permeation enhancers. Based on experimental
solubility values, the GastroPlus software can be applied to predict in vivo performance of the drug solution in a particular
solvent (permeation enhancer) responsible for maximized solubility
depending on the experimental solubility, Hansen solubility (HSPiP
software), and thermodynamic parameters.[10] Moreover, the software can predict the effect of physicochemical
properties of the drug for improved permeation across the human skin.
Thus, the solubility of KETO in these permeation enhancers and their
validation parameters (thermodynamic and computational models) are
required in pre-formulation study.In this study, HSPiP assisted
to select the most relevant organic
solvent (permeation enhancers) based on three solubility parameters
(three-dimensional Hansen solubility and space parameters), which
are designated as δd as the dispersion parameter,
δp as the polarity parameter, and δh as the hydrogen parameter. The solubility study was conducted over
various temperature range (T = 298.2 to 318.2 K)
and fixed pressure (P = 0.1 MPa). The study was performed
at a temperature below its melting point (146.7 °C) (Figure B). These parameters
were modeled to correlate the experimental solubility data. Furthermore,
the apparent thermodynamic analysis and computational models regressed
the experimental data and validated the studied solubility models,
respectively. Molecular interaction between the drug and solvents
was also studied. Finally, the GastroPlus simulation and prediction
modules investigated major factors affecting the solubility of the
drug and pharmacokinetic parameters when formulated for oral or topical
delivery in the best solvent.
Results and Discussion
Characterization of KETO
in the Solid Phase
KETO is
a highly crystalline compound with poor aqueous solubility. The pure
drug and equilibrated KETO (with methanol) were characterized for
solid phases using a differential scanning calorimeter (DSC), and
the result (thermogram) is illustrated in Figure B. A characteristic endothermic peak indicated
a fusion temperature (T) along with
the marked value of the fusion enthalpy (ΔH). The observed values of T and ΔH were 146.84 °C
and 107.8 J/g, respectively, as indicated in the characteristic endothermic
peak of the thermogram (Figure B). Moreover, these values (T and ΔH) were observed to be
146.92 °C and 107.62 J/g (Figure B), respectively, for equilibrated KETO obtained from
well-resolved sharp peaks. It is obvious from the thermogram that
both of them (pure KETO and equilibrated) are stable and remained
in a crystalline solid state. There were no visible changes in solid-state
characteristic thermal parameters (T and ΔH) during solubility assessment.
The reported value of T of KETO was
146.0 °C, and there is no observed degradation beyond the melting
point of KETO during thermal analysis.[11] The finding is in close agreement with the experimental value (146.8
°C).
Experimental Solubility Data
The results of experimental
solubility in various organic permeation enhancers are presented in Table . These are biocompatible
and well-established skin permeation enhancers already explored in
various topical and transdermal drug delivery. Moreover, several organic
solvents (2-propanol, ethanol, PEG200, PEG400, and PEG600) have been
investigated for improved solubility of KETO intended for pharmaceutical
application.[2,12] Improved solubility in the explored
permeation enhancer could be an ideal component for topical or transdermal
delivery in the treatment of various dermal fungal infections. Therefore,
the solubility of KETO in these permeation enhancers were envisaged
and investigated for quantitative analysis followed by validation
using thermodynamic and computational models. The software HSPiP assisted
to screen the most suitable permeation enhancer based on the solubility
parameters (dispersion, polarity, and hydrogen bond) and chemical
structure of the drug (Figure A and Table ).
Table 1
Mole Fractional Experimental Solubility
(x) of Ketoconazole at Varied Temperatures T = 298.2–318.2 K and Pressure = 0.1 MPaa
temperature
(K)
solvent
298.2 K
303.2 K
308.2 K
313.2 K
318.2 K
ethanol
2.1× 10–4
2.8× 10–4
3.7×
10–4
4.9× 10–4
5.6× 10–4
DMSO
2.5× 10–4
2.9× 10–4
3.4× 10–4
4.2×
10–4
4.9× 10–4
ethylene glycol
0.2× 10–4
0.3× 10–4
1.0× 10–4
1.3×
10–4
1.7× 10–4
oleic acid
5.8× 10–3
6.3× 10–3
6.9× 10–3
7.5×
10–3
8.5× 10–3
span 80
4.7× 10–3
5.1× 10–3
5.7× 10–3
6.2×
10–3
6.9× 10–3
limonene
5.1× 10–3
5.5× 10–3
6.1× 10–3
6.8×
10–3
7.3× 10–3
eugenol
3.5× 10–3
3.7× 10–3
4.1× 10–3
4.2×
10–3
4.5× 10–3
THP
3.2× 10–3
3.4× 10–3
3.9× 10–3
4.3× 10–3
4.9×
10–3
labrasol
2.8× 10–3
3.1× 10–3
3.5× 10–3
3.9×
10–3
4.4× 10–3
propylene glycol
0.1× 10–4
1.2× 10–4
1.6× 10–4
2.3×
10–4
2.8× 10–4
xidl
0.38 × 10–3
0.53 × 10–3
0.74
× 10–3
1.01 × 10–3
1.37 × 10–3
DMSO = Dimethyl sulfoxide; THP =
transcutol HP. The standard uncertainties u are u(T) = 0.10 K, u(P) = 0.004 MPa and u(x) = 1.5%.
Table 2
Various Hansen Solubility (x) Parameters
of KTZ in Various Permeation Enhancers
(Solvents)a
DMSO = Dimethyl sulfoxide; THP =
transcutol HP. The standard uncertainties u are u(T) = 0.10 K, u(P) = 0.004 MPa and u(x) = 1.5%.IPA = isopropyl alcohol; IPM = isopropyl
myristate; THP = transcutol HP; EA = ethyl acetate.Table summarizes
the experimental values (x) of KETO in
the organic solvents at an explored temperature range (Table ) wherein the values of x were found to be constantly increasing with
temperature (p < 0.05). The maximum x solubility values of KETO were obtained in oleic
acid (8.5× 10–3) and limonene (7.3× 10–3) at T = 318.2 K. The values of experimental
solubility in all solvents can be ordered as oleic acid > limonene
> span 80 (6.9× 10–3) > THP (4.9×
10–3) > eugenol (4.5× 10–3) > labrasol
(4.4× 10–3) > DMSO (4.9× 10–4) > ethanol (5.6 × 10–4) > propylene
glycol
(2.8× 10–4) > ethylene glycol (1.7×
10–4) performed at a temperature of 318.2 K. The x values followed the same trend at temperatures
of T = 298.2 K, T = 303.2 K, T = 308.2 K, and T = 313.2 K. It is noticeable
that the x values were significant (p < 0.05) in oleic acid, limonene, and span 80 compared
to others. This can be explained based on the correlation of the HSPs
values of oleic acid, limonene, and span 80 with that of the HSPs
values of pure KETO. The values of δd, δp, and δh of KETO are 21.6, 11.9, and 6.2,
whereas these values for oleic acid were predicted to be 16.1, 7.3,
and 5.8, respectively. The polarity parameter values of oleic acid,
eugenol, span80, and THP are comparable and much lower than the hydrophilic
solvents (labrasol and ethanol). KETO molar solubility values in ethanol
were found to be 2.1 × 10–4, 2.8 × 10–4, 3.7 × 10–4, 4.9 × 10–4, and 5.6 × 10–4 at T = 298.2 K, T = 303.2 K, T = 308.2 K, T = 313.2 K, and T =
313.2 K, respectively. Recently, the drug molar solubility values
in ethanol were reported to be 2.2 × 10–5,
2.6 × 10–5, and 2.9 × 10–5 at T = 298.2 K, T = 303.2 K, and T = 308.2 K, respectively.[2] The
slight differences at the corresponding temperatures may be due to
differences in pressure (0.1 MPa). However, the differences in the
molar solubility with the increase in temperature were not significant,
which are in accordance with the reported pattern. Moreover, Hashemzadeh
and Jouyban did not investigate the molar solubility in ethanol at
298.2 and 318.2 K.[2] The drug is poorly
water soluble being crystalline in nature. Therefore, the increased
drug solubility may be correlated with the lipophilic–lipophilic-enabled
(solute–solvent) interaction (like dissolves like). On the
other hand, labrasol, ethanol, propylene glycol, and ethylene glycol
exhibited quite lower values of x, which
are due to the high polarity δp value of HSPs (Tables and 2) at T = 318.2 K. Oleic acid and span 80
showed about similar values of HSPs parameters, which may be a reason
for closeness in experimental solubility (x), space parameter (R), and total solubility
(Δδ) values as shown in Table .[14] The mole fractional
experimental solubility values of KETO in ethylene glycol and propylene
glycol are 1.7 × 10–4 and 2.8 × 10–4, respectively, which may be due to higher values
of δh (26.4 for ethylene glycol and 21.8 for propylene
glycol) compared to KETO (6.2). This may have led to limited interaction
(hydrogen bonding interaction) between the drug and solvent resulting
least solubility (Tables and 2). Ethylene glycol showed an
approximate value of the δp (11.1), which was close
to that of the drug (11.9). However, the drug was found to be the
least soluble, which may be due to weak dispersion in the solvent
(δp = 17.2). In this context, the drug was found
maximally solubilized in oleic acid due to poor polarity of the solvent
and hydrophobic–hydrophobic facilitated interaction. Thus,
the solvents such as oleic acid, THP, span 80, and limonene can be
proposed as suitable solvents for developing formulation intended
for transdermal or topical delivery of rifampicin working as a carrier
as well as permeation enhancer if laden with the drug.
Solubility
Parameters of KETO and Studied Solvents using Various
Models
We used all of the HSP parameters for the drug and
solvents as shown in Table . The value of δ of KETO was predicted to be 25.4 MPa1/2 and polarity parameter was estimated to be 11.9 MPa1/2 suggesting weak interaction with hydrophilic/polar solvents.
Therefore, the drug was found to have maximum x data in a permeation enhancer with high hydrophobicity
and low polarity (δp) (oleic acid, THP, span 80,
and limonene). It is noteworthy that calculated values of R for oleic acid (6.6), span 80 (6.7), limonene
(5.92), eugenol (5.14), and THP (4.13) were <10.0 MPa1/2, suggesting augmented miscibility of the drug in these solvents.
In general, the value of R of <5.6
MPa1/2 is considered as “good soluble” or
“miscible of solute”.[13,14] However, there
are contradictory findings among the literature values. Few authors
correlated this value as soluble (around 10 MPa1/2).[14] In the our case, the values of R for limonene, eugenol, THP, span 80, and oleic acid
are in the range of 5.6–8.0 MPa1/2 and these could
be considered as the most suitable permeation enhancers for topical
or transdermal delivery. There are few reports where authors could
not find any values of the R value close
to 5.6 MPa1/2 in all explored solvents. However, they agreed
and defined the solubility of the solute as soluble considering the R value of 8.0 close to 5.6 MPa1/2.[15] Thus, THP, limonene, span 80, oleic
acid, and eugenol can be considered as a first series of solvents
for good solubility/miscibility of KETO among them. Furthermore, the
values of other parameters such as Δδ* and Δδ
were estimated in the solvents. The values of Δδ ranged
from 0.18 to 4.74 MPa1/2 for the studied solvents, which
indicated within the acceptable range (<10.0 MPa1/2).
This parameter (Δδ) was minimum for ethylene glycol (0.18
MPa1/2), propylene glycol (0.42 MPa1/2), and
eugenol (0.41 MPa1/2), as shown in Table . As per the literature, the value of Δδ
of <7.0 MPa1/2 was considered as the most soluble or
miscible of a solute in a given solvent.[16] Considering the values of R and Δδ,
limonene, eugenol, and THP are the most preferred solvents being capable
of solubilizing hydrophobic KETO. In the case of propylene glycol
and ethylene glycol, the values of Δδ, are the least but
the R values are quite high. This might
be due to the fact that the dispersion ability of the drug as observed
in the δd, of the Hansen solubility parameter for
eugenol (δd = 19.0) is the closest value to KETO
(21.6). Similarly, the Δδ* values of KETO were determined
using van Krevelen and Hoftyzer equations. However, the value of Δδ
of <5.0 MPa1/2 is good for improved solubility or miscibility.[15,16] The values of Δδ* are found to be ≥10.0 MPa1/2 in all explored permeation enhancers except THP (2.93 MPa1/2) as shown in Table . A solvent is selected with the lowest value of Δδ*
of the Hansen solubility parameter. The estimated values of Δδ*
were observed to be 2.93, 10.0, and 10.41 MPa1/2 for THP,
labrasol, and limonene, respectively, wherein the THP exhibited the
minimum value. Thus, these Hansen solubility parameters (R, Δδ*, and Δδ) are in an
acceptable range as compared to other solvents, which showed good
solubility of KETO in THP. Thus, THP could be considered as the most
suitable solvent (permeation enhancer), whereas ethylene glycol is
the solvent with poor solubility of KETO. There is a correlation that
exists between the solubility of a solute in a solvent and their solubility
parameters. In addition, several factors are responsible for KETO
solubility in the solvent and these are the molar mass volume and
molecular interaction (inter and intra).[15] The objective of the study was to select a permeation enhancer with
dual functionality (permeation enhancer and carrier) in developing
topical or transdermal formulation. Therefore, considering Hansen
solubility parameters and space parameter (R), THP could be the best permeation enhancer and suitable solvent
when fabricated in a nanocarrier system intended for topical or transdermal
delivery.
Estimation of Ideal Solubility (xidl) and Activity Coefficient (Υ)
These values were estimated to identify the most suitable solvent
responsible for maximum solubility of KETO and serving as the potential
permeation enhancer. Moreover, the estimated value of Υi assists to find a molecular interaction between the solute
and the solvent. Initially, the xidl of
KETO was estimated to calculate the value of the activity coefficient. Tables and 3 summarize the values of xidl and
Υi of KETO in various permeation enhancers, respectively. The
ideal solubility values (xidl) of KETO
were found to be 0.38 × 10–3 to 1.37 ×
10–3 at T = 298.2 to 318.2 K (Table ). The experimental
solubility xe of KETO in oleic acid was
found to be significantly (p < 0.05) higher than
the ideal solubility (xidl) values at T = 298.2 and 303.2 K, whereas this pattern decreases beyond
the temperature of 303.2 K (Table ). Ethanol, DMSO, ethylene glycol, and propylene glycol
showed experimental solubility values of KETO lower than the ideal
solubility as shown in Table . Similarly, oleic acid, span 80, limonene, eugenol, and THP
exhibited significantly (p < 0.05) higher values
of xe as compared to xidl over all studied temperature points, which could be
basis for considering these solvents suitable for KETO solubilization.
Table 3
Activity Coefficient (Υ) of Ketoconazole at Varied Temperatures (T = 298.2–318.2
K)a
Υi
solvent
298.2 K
303.2 K
308.2 K
313.2 K
318.2 K
ethanol
1.81
1.89
1.98
2.05
2.44
DMSO
1.52
1.83
2.16
2.41
2.79
ethylene glycol
1.93
3.65
7.35
7.75
8.06
oleic acid
1.65
1.84
1.76
1.84
2.61
span 80
0.80
1.04
1.28
1.62
2.21
limonene
0.74
0.96
1.20
1.48
1.87
eugenol
1.00
1.43
1.69
1.85
1.98
THP
0.11
0.56
0.88
1.03
1.18
labrasol
1.35
1.71
2.10
2.58
3.11
propylene glycol
3.80
4.43
4.59
4.83
4.98
DMSO = dimethyl sulfoxide; THP =
transcutol HP.
DMSO = dimethyl sulfoxide; THP =
transcutol HP.The estimated
values of activity coefficient (Υ) of KETO in 10 permeation enhancers at the temperature
range of T = 298.2–318.2 K are tabulated in Table . The values were
in the range of 0.75–1.87, 1.0–1.98, and 0.11–1.18
in limonene, eugenol, and THP, respectively. Moreover, the Υ values were relatively higher in DMSO, ethylene
glycol, propylene glycol, labrasol, and ethanol as compared to THP,
limonene, and eugenol estimated at T = 298.2 K, 303.2,
308.2, 313.2, and 318.2 K. That may rationalize that these three solvents
might have maximized the solute–solvent molecular interaction,
which can be ordered as “KETO-THP > KETO-limonene > KETO-Eugenol”
combination. Improved solubilization in THP may be attributed to formation
of intermolecular hydrogen bonding between the hydroxyl group of THP
and the imidazolenitrogen atom.[18,19] Conclusively,
THP, limonene, and eugenol may be the most preferred solvents to solubilize
KETO.
Computational Validation
The objective of the study
was to investigate a suitable permeation
enhancer working as a solvent to solubilize KETO and a potential skin
permeation when formulated as topical or transdermal formulation.
Therefore, experimental solubility data were generated at various
temperatures (selected based on Hansen solubility parameters). The
data needed to be validated using two known validation computational
models such as the Apelblat model and vanʼt Hoff model. Using
both of them, a graphical correlation was established between the
lnx and lnxapl of KETO as a function of 1/T (Figure ). The computational validation
results are presented in Table , which corroborated a good correlation between lnx and lnxapl (Figure ). Moreover, the
estimated values of the percent relative mean square deviation (%RMSD)
and overall %RMSD of the drug in all studied solvents were 0.011–0.848
and 0.136, respectively (Table ). In Table , the values of A, B, and C represent the Apelblat solubility parameters, which were
estimated using the Apelblat equation. To analyze this model for each
solvent, the value of r2 (regression coefficient)
was found to be ≥0.99, vindicating a good correlation of lnx of KETO in all studied solvents.
Figure 2
Correlation
of lnx values of ketoconazole
with the Apelblat model in various organic solvents as a function
of 1/T.
Table 4
Apelblat
Equation Parameters for Various
Permeation Enhancers (Solvent)a
Correlation
of lnx values of ketoconazole
with the Apelblat model in various organic solvents as a function
of 1/T.DMSO = dimethyl sulfoxide; THP =
transcutol HP; RMSD = root mean square deviation.Similar experimental analysis was
carried out using the vanʼt
Hoff model wherein a graphical correlation between lnx and lnxvant as a function
of 1/T was demonstrated, suggesting a good correlation
(Figure ). Likewise,
the estimated values of the %RMSD, overall %RMSD, model parameters
(a and b), and regression coefficient
are presented in Table . The estimated values of %RMSD and overall %RMSD were found to be
0.011–0.178 and 0.0478, respectively (Table ) for all studied solvents. The estimated
values of r2in each solvent were found
to be ≥0.09. Thus, both models validated the experimental solubility
data studied in various solvents at varied temperatures by establishing
a good graphical correlation and estimating model parameters.
Figure 3
van’t
Hoff plot for ketoconazole plotted between lnx and (1/T – 1/Thm) for the drug in various organic solvents.
Table 5
Vanʼt Hoff Model and Parametersa
parameters
solvent
a
b
r2
RMSD
overall RMSD
ethanol
58.84
–17256.2
0.9888
0.041
DMSO
41.062
–11546.0
0.9998
0.042
ethylene
glycol
52.119
–14865.8
0.9989
0.076
oleic
acid
47.545
–12489.5
0.9973
0.178
span
80
48.508
–13094.3
0.9998
0.023
0.0478
limonene
41.238
–10805.4
0.9975
0.013
eugenol
19.403
–4744.86
0.9939
0.013
THP
29.123
–7763.6
0.9999
0.010
labrasol
28.137
–7577.06
0.9998
0.017
propylene
glycol
26.376
–7589.08
0.9776
0.065
DMSO = dimethyl sulfoxide; THP =
transcutol HP.
van’t
Hoff plot for ketoconazole plotted between lnx and (1/T – 1/Thm) for the drug in various organic solvents.DMSO = dimethyl sulfoxide; THP =
transcutol HP.
Thermodynamic Parameters
Thermodynamic functional parameters
are required to explain the mechanistic view of KETO solubility in
individual solvent at various temperatures. These function parameters
are based on physical changes (events) and represented as ΔsolΔG°, ΔsolΔH° and ΔsolΔS° in a mathematical equation. We rationalized the process of
KETO solubility in studied solvents by thermodynamic analysis and
using three thermodynamic solubility function parameters.[20] These functional parameters were estimated for
KETO in various solvents and are presented in Table . The calculated values of ΔsolΔG°, ΔsolΔH° and ΔsolΔS° were found in the range of 1195.7–10820.7, 13071.9–22501.2,
and 28.4–56.92 kJ mol–1, respectively, in
the investigated solvents. It is apparently clear from the result
that oleic acid, span 80, limonene, eugenol, and THP showed relatively
low values of the free energy (ΔsolΔG°) of dissolution as compared to other solvents. Similarly,
limonene, eugenol, and THP showed the values of ΔsolΔS° to be 27.07, 22.34, 20.2 kJ mol–1, respectively, which were the minimum values among
them. These solvents can be ordered for ΔsolΔS° as limonene > eugenol > THP, suggesting THP
as the
most suitable solvent for KETO. The estimated values of ΔsolΔS° were the maximum in ethanol,
DMSO, ethylene glycol, and propylene glycol, which indicated that
these solvents could be considered as solvents for poor solubility
of KETO due to hydrophilicity and high polarity solvent resulting
in weak solute–solvent molecular interaction (Table ). As per the concept of thermodynamics,
a reaction or a process is said to be spontaneous (negative free energy)
when the change in free energy ΔsolΔG° decreases. Thus, KETO solubilization in limonene,
THP, and eugenol was a spontaneous process resulting in a significant
change in ΔsolΔG°, providing
a suitable thermodynamic environment for increased solubility.[20] In addition, the lower values of ΔsolΔS° for THP, limonene, and eugenol
further supported a reasonable explanation for the increased solubility
of KETO in these permeation enhancers. It is quite interesting to
note that the negative enthalpy values of dissolution in limonene,
eugenol, and THP may be due to the possible hydrophobic interaction
with the non-polar functional groups (methyl, methylene, and aromatic
rings) of KETO as shown in Figure A.[21] Apart from these, there
are several factors responsible for the solubility of KETO in these
solvents or permeation enhancers. These are physicochemical behavior
of the solute and solvent, hydrogen bond formation with non-polar
groups of the drug, solute–solvent interaction, and co-solvency
using a binary mixture of organic solvent with water. Very recently,
it was reported that ethanol used as co-solvent with water increased
the solubility of KETO due to breaking the ordered structure of water
stabilized with hydrogen bonding around the non-polar groups of KETO,
which caused increased values of enthalpy and entropy of the system.[21]
Table 6
Summary of Thermodynamic
Functional
Parameters for Validationa
parameters
solvent
Δsol ΔH° (kJ mol–1)
Δsol ΔG° (kJ mol–1)
Δsol ΔS° (kJ mol–1)
r2
ethanol
–4773.9
–20115.76
51.33
0.9767
DMSO
–3254.3
–20461.3
56.41
0.9948
ethylene glycol
–10820.0
–19373.2
58.04
0.9357
oleic acid
–1778.8
–14273.34
30.96
0.9987
span 80
–1826.8
–13267.2
37.51
0.9975
limonene
–1763.6
–13071.89
27.07
0.9947
eugenol
–1195.7
–14109.0
22.34
0.9753
THP
–1982.3
–14243.42
20.20
0.9998
labrasol
–2150.0
–14519.8
40.55
0.9982
propylene glycol
–5138.1
–22501.2
56.92
0.9865
DMSO = dimethyl
sulfoxide; THP =
transcutol HP.
DMSO = dimethyl
sulfoxide; THP =
transcutol HP.
GastroPlus
Prediction Studies
The software program
is basically to simulate in vitro data and prediction
of in vivo performance based on the input parameters
(Table ). We added
the values of in vitro drug release in in
vitro data tab for pure KETO and THP-solubilized drug. Neat
KETO (suspension) exhibited % drug releases of 8.4, 12.0, 25.1, 31.6,
and 39.9% at the time points of 0.5, 1, 2, 4, and 8 h, respectively,
in phosphate buffer solution (pH 7.4). Similarly, THP-solubilized
KETO exhibited % drug releases of 25.7, 56.9, 67.3, 75.2, and 87.7%
at the same time points. The release data was also modeled for the
Weibull release distribution pattern using the GastroPlus simulation.
The results are illustrated in Figure A,B. Figure A and Figure B shows the in vitro release pattern of the neat
KETO suspension and THP-solubilized drug (10 mg/mL), respectively.
The neat KETO suspension and THP-solubilized drug revealed maximum
drug releases of 39.9 and 87.7% at the end of 8 h, respectively. The
Weibull-modeled graph (single Weibull) showed that the release distribution
followed a sigmoidal pattern as evidenced with shape factors (b shape
values) of 1.47 and 1.57, for suspension and THP-solubilized KETO
(blue solid lines of Figure A,B). It is obvious from the release graphs that this model
may not be the only prefect release model to confirm immediate and
controlled release behavior of the drug. However, all of the other
parameters affecting the drug release (such as pH, amount, pKa, polarity,
logP, density, and temperature) should be figured out and controlled.[22,23]
Table 7
Summary of the Input
Parameters of
Ketoconazole for the GastroPlus-Based Prediction Study
input parameters
value
empirical formula
C26H28Cl2N4O4
molecular weight (g/mole)
531.04
melting point (°C)
146
log P value
4.35
pKa
3.96 (amine) and 6.74 (imine)
aqueous solubility (mg/ml at 25 °C)
0.24
apparent permeability (×10–4 cm/s)
0.75
dosing volume (mL)
1.0
dose (mg)
2.0
body weight (Kg)
60.0
total clearance (L/h)
8.66
elimination half-life
(h)
8.0
volume of distribution (L/Kg)
0.36 (25.41 L)
protein binding capacity
(%)
84
simulation time (h)
12
Figure 4
GastroPlus-based
simulation and prediction study: (A) In
vitro drug release behavior and Weibull model distribution
of neat ketoconazole suspension (blue line for sigmoidal release pattern),
(B) in vitro drug release behavior and Weibull model
distribution of THP solubilized ketoconazole (blue line for sigmoidal
release pattern) in buffer solution (pH 7.4), (C) skin absorption
of neat ketoconazole from suspension, and (D) skin absorption of THP-solubilized
ketoconazole.
GastroPlus-based
simulation and prediction study: (A) In
vitro drug release behavior and Weibull model distribution
of neat ketoconazole suspension (blue line for sigmoidal release pattern),
(B) in vitro drug release behavior and Weibull model
distribution of THP solubilized ketoconazole (blue line for sigmoidal
release pattern) in buffer solution (pH 7.4), (C) skin absorption
of neat ketoconazole from suspension, and (D) skin absorption of THP-solubilized
ketoconazole.Furthermore, the software PBPK model
predicted the amount of the
drug permeated across human skin (70 Kg) when applied to the skin
(arm). The predicted values of KETO cream (considering pure drug =
0.2 mg) and THP-solubilized KETO (0.2 mg as solution) are illustrated
in Figure C and 4D, respectively where the neat drug cream and THP-solubilized
KETO showed 38.0% and 79.1%, respectively. This may be correlated
with improved solubilisation and permeation potential of THP explored
for several poor soluble drugs. This skin penetration and permeation
may be attributed to the facilitated drug portioning and diffusion.
The THP is reported as the most suitable skin permeation enhancer
possibly due to capable of increasing flux (21 times higher) and diffusion
coefficient (17 times) higher than the hydrated skin.[23]The neat KETO is a hydrophobic and weak water soluble
molecule.
However, THP-solubilized KETO was anticipated to have high permeation
across human skin on topical application and enhanced absorption through
intestinal membrane when administered oral. Therefore, the software
based prediction study suggested that the dissolution rate (0.1 mg
as input parameter of topical dose) of the drug and skin absorption
(at pH 5.6 as simulated pH of human skin) was within 1 h as shown
in Figure . The inset
graph of Figure depicted
the immediate absorption (in vivo) profile of THP-solubilized
KETO when administered orally. This could be possible due to improved
drug solubility and enhanced permeation attributed to the solvent
(THP).[23] However, the preclinical study
using a suitable animal requires generating a complete proof of concept
for topical/transdermal/oral formulation of KETO using THP as a solvent
and permeation enhancer.
Figure 5
GastroPlus-based prediction of a relationship
between dissolution
and skin permeation of ketoconazole dissolved in THP. The inset of
the figure predicted the plasma concentration time profile of THP
solubilized ketoconazole when administeresd orally (0.1 mg).
GastroPlus-based prediction of a relationship
between dissolution
and skin permeation of ketoconazole dissolved in THP. The inset of
the figure predicted the plasma concentration time profile of THP
solubilized ketoconazole when administeresd orally (0.1 mg).
Significance of the Explored Permeation Enhancers
In
this study, the term “solvent” was used collective for
the organic solvent, lipid, and surfactants responsible for improved
solubilization and skin permeation if laden with the drug. KETO is
a choice drug for several topical fungal diseases, which need to be
addressed with new excipients exhibiting dual functionality such as
solubilization as well as skin permeation. Based on the Hansen solubility
parameter, 10 solvents were predicted for KETO solubility and possible
interaction. The solubility experimental data were validated using
thermodynamic functional terms and computational models. Thus, the
result of this study would assist formulation scientists (transdermal
and topical) during the preliminary study for the selection of the
organic phase considering the solubility and skin permeation enhancer.
We found limonene (terpene), eugenol, and THP as the most suitable
solvents (permeation enhancer) intended for topical and transdermal
formulation. In several literature studies, these excipients are well
established for the skin permeation potential of poor soluble drugs.
There is scarcity of in vivo data in human to establish
a direct correlation with in vitro findings. However,
we predicted in vitro release kinetics, the drug
absorption across human skin (left arm), and compared between the
neat drug and THP-solubilized KETO using the GastroPlus predictive
modules.
Conclusions
KETO is extremely poorly
soluble in water and a well-established
antifungal candidate to control cutaneous fungal infections. Data
of experimental and Hansen solubility parameters suggested that several
permeation enhancers can be a suitable option for the drug solubilization
and skin permeation enhancing effect. The thermodynamic functional
parameters and computational models validated the experimental solubility
carried out at varied temperature. No transformation occurred in KETO
extracted from methanol as evidenced by the DSC result. Two models
such as the vanʼt Hoff and Apelblat were employed to validate
the results of experimental solubility. All of the solvents exhibited
a significant (p < 0.05) proportional relationship
of the experimental solubility values with temperature. This may be
rationalized that these three solvents were found to have maximum
solute–solvent molecular interaction, which can be ordered
as KETO-THP > KETO-limonene > KETO-Eugenol combination at T = 318.2 K as compared to other combinations. The GastroPlus
program software predicted a maximized drug content permeated (THP
solubilized) in human skin as compared to the drug solution. Moreover,
there was a good correlation between in vitro drug
dissolution and permeation (absorption across the skin) when predicted
for THP-solubilized construct (immediate release pattern < 1 h).
The software predicted an immediate release type of oral absorption
for THP-solubilized KETO. The findings suggested that transcutol may
also be an ideal alternative as solvent and skin permeation enhancer
for topical delivery of KETO to control fungal infection.
Experimental
Methods
Materials
KETO was procured from Sigma-Aldrich, (India).
Transcutol HP and labrasol were obtained as ex gratia from Gatteffosse (36 chem de Genas-BP 603-F-69804 Saint Priest Cedex
France). Span 80, ethanol, ethylene glycol, oleic acid, eugenol, limonene,
DMSO, and ethanol were purchased from Merck Chemicals Mumbai, India.
All of the reagents were of analytical grade.
Analytical Methodology
The drug was assayed using a
validated HPLC (high-performance liquid chromatography, Waters, Empower
2 software, USA), and the procedure was adopted as per the reported
method.[24] Analysis was performed using
a reverse phase C18 column (150 mm × 46 mm, 5 μm), at a
flow rate of 1 mL/min and UV detector at 254 nm. The mobile phase
was composed of acetonitrile, water, and diethylamine (70:30:0.05,
v/v). The mobile phase was filtered, sonicated, and then used in the
system using 10 μL as the injection volume (sample). The set
run time was 10 min with a constant operating temperature of 20 ±
1 °C (Figure C). The sensitivity of the analysis was 0.005 to 0.010 μg/mL
with a regression coefficient (r2) of
0.9999. The final pH of the mobile phase was adjusted to 9.0 using
a 0.01 N NaOH solution.[25]
In order to observe
any possible transition in analytical solvent,
pure KETO was completely recovered from the equilibrated KETO in methanol
(slow evaporation method) and assessed for thermal parameters (fusion
temperature and enthalpy) using a DSC method (DSC-50, Shimadzu, Japan).
This analysis was conducted to find probable chances of transition
in the explored organic solvents, possible impurities, and drug degradation
over the studied temperature range. An accurately weighed amount (4.0
mg) of both samples (pure and recovered) were transferred into an
aluminum pan, sealed (hermatically), and then kept in the furnace
chamber (sample holder). The samples were heated at the heating rate
of 10 °C/min till 200 °C followed by cooling after completion
of heating (nitrogen flow of 20.0 mL/min) for the next sample. The
result of DSC was presented in DSC spectral peaks containing the values
of endothermic peaks and fusion enthalpy (ΔHfusion J/g). The DSC cell was calibrated using indium
(melting point of 156.8 °C and ΔHfusion of 28.71 J/g).
Solubility Assessment
The experimental
solubility (x) of KETO was studied in
PG (propylene glycol),
labrasol, THP (transcutol HP), eugenol, limonene, span 80, oleic acid,
ethylene glycol, DMSO, and ethanol, which are of GRAS (generally regarded
as safe) organic solvents and major skin permeation enhancer in topical
formulations. The study was performed at five temperature points (T = 298.2, 303.3, 308.2, 313.2, and 318.2 K) and constant
pressure (0.1 MPa) following the reported method.[7] In brief, the weighed amount of KETO was added to 5 mL
of each organic solvent separately followed by shaking in a water
bath shaker for 12 h (Remi Equipment Pvt. Ltd., Mumbai, India). The
study was continued till equilibrium was attained between the dissolved
and undissolved KETO. The dissolved content (μg g–1) was estimated using validated HPLC at a λmax of
254 nm. Analysis was carried out in triplicate (n = 3) for mean and ± SD values.where m1 and M1 are the mass and the molar
mass of KETO, respectively. Similarly, m2 and M2 represent the mass and the molar
mass of the solvent, respectively.
Solubility Parameters
Hildebrand and Scott introduced
the idea of the solubility parameters based on the solubility behavior
of the solute in a specific solvent.[26] Hildebrand
and Scott considered that the inherent cohesive energy (criterion
of attractiveness) of any solute is a necessary factor to separate
molecules or ions or atoms from the parent compound and is related
to the solubility parameters.[27] It is noticeable
that the solubility of any solute is maximum when the difference between
the polarity parameter of the solute (δps) and the
solvent is approximately zero [Δ(δps –
δpv) = 0].[10] The Hildebrand
principle could be applied to the simple liquid mixture being used
in pharmaceutical manufacturing such as oral solution, parenteral
product, and topical formulation (solution). However, this concept
does not fit for the complex pharmaceutical mixture based products.
For this, the principle was further extended by establishing new approach
named as the Hansen approach to understand the complex mixture and
associated interactions between the solute and the solvent. Theoretically,
the Hansen theory depends upon the divided individual component of
the total cohesive energy (δt) arising from the dispersion
force (δd), molecular dipole–dipole interactions
(δp) and the hydrogen bond (δh).[28]In a new approach,
the three-dimensional Hansen solubility parameter (3D-HSP, δ)
was obtained by the sum of the square of the individual parameters:Thus, 3D-HSP (δ) of KETO
and individual solvent was calculated
using HSPiP software (version 5.0.1, Louisville, KY, USA) using eq . The individual parameters
such as dispersion, polarity, and hydrogen bonding are indicated as
δd, δp, and δh,
respectively, which are three prime Hansen solubility parameters responsible
for main interactions between the solute and organic solvent.During product development and generation proof of concept, researchers
and formulation scientists need to understand the basic fundamental
working in the solubility and the molecular interactions. These interactions
exist between the solute–solvent, solvent–polymer, and
solute–solvent. Thus, there are various established approaches
based on the concept of solubility parameters or the “like
dissolves like” theory. Van-Krevelen and co-workers presented
a modified solubility parameter Δδ for explaining the
mixing mechanism of two substances by eq .[16,17]In order to describe the maximum probable miscibility
of the solute
in the solvent or between the two components, a threshold reported
to be Δδ ≤ 5.0 MPa1/2, wherein the Δδ
value could be considered less miscible or higher than 10, is regarded
as immiscible. In this context, the term “miscibility”
refers to a solution comprising of a solute (of certain molar concentration)
in a particular solvent at a certain temperature.In addition,
Bagley presented a conceptual thermodynamic relationship
between two solubility parameters (δd and δp). This is known as a combined solubility parameters (δv)
as given in eq :Equation can be applied to project
the 3D solubility
parameter space (R) into a 2D plot. This
plot was drawn between δv and δh, known as Bagley plot. This R was used
to estimate a level miscibility or solubilization between two components
or substances. The solubility parameter space (R) is a distance in the Bagley plot, which represents the
solubility of any solute in a particular solvent. Mathematically,
the value of R can be determined using eq :Notably,
this equation (Bagley
plot) was the best fit model to estimate the solubility/miscibility
of a polymer or an active drug or solute in a particular solvent/excipient.
Furthermore, Greenhalgh established a new model for the miscibility
of two substances, which was based on the differences of Δδt (the total solubility parameters). This can be calculated
using eq :In this model, it was established
that two substances or compounds are said to be completely miscible
when Δδt ≤ 7.0 MPa1/2 and
immiscible when Δδt ≥ 10.0 MPa1/2. It is crucial to divide Δδt into its components
(δd, δp, and δh), and the major limitation of this approach is the estimation of
partial solubility.Ideal solubility (xideal) and activity
coefficient (Υ)Fundamentally,
a compound or substance or solute is considered
in an equilibrium state of an ideal solution. Moreover, the free energy
(G) or partial molar G of any compound
or substance (crystalline solute) must be equal to the saturated solution
of the same solute, which can be expressed as eq :In the case
of an irreversible
process, the total energy of such process is the sum of all involved
reversible processes between the same points (Kirchoffʼs law).
That is why the irreversible enthalpy (at temperature T as melting point of the solute) represents the sum of all reversible
enthalpies. The xideal of any solute in
a particular organic solvent or permeation enhancer can be presented
as eq where ΔH, ΔCpm and T are the enthalpy of melting,
the difference of the molar
heat capacity of the solid state with that of the liquid state, and
the fusion temperature of the solute, respectively.[29]Mathematically, the value of ΔC can be estimated using eq where the values of T and ΔH were
estimated to be 419.0 K and 57.28 kJ mol–1, respectively
(Figure B) by DSC
analysis. Thus, the calculated value of ΔC for pure KETO was 43.79 J mol–1 K–1 using eq . Notably, it is obvious from eq that an ideal solubility or the crystal–liquid
solubility ratio is dependent upon the melting point of the solute
only and the solvent has no effect.[30] The
values of xideal and activity coefficient
(Υ) of KETO were estimated in various
solvents using eqs and 11, respectively:In the present study, the
experimental solubility was estimated
in various organic solvents (permeation enhancers), which need to
be validated using computational validation models. These models (Apelblat
model and vanʼt Hoff model) are based on a thermodynamic concept.[31,32] The apelblat solubility (xapl) of KETO
was calculated using eq :where A, B, and C are the Apelblat solubility
parameters
estimated from the experimental solubility data (Table ) using the nonlinear multivariate
regression analysis method. The x values
of KETO in various solvents were modeled with the xapl data using relative means square deviation (% RMSD)
and regression r2 values (Figure ). The % RMSD values can be
estimated using eq where N is
the number experimental data points in the current study. Similarly,
the vanʼt Hoff model solubility was estimated using eq where a and b are the vanʼt Hoff solubility
parameters at temperature T and estimated by plotting
the ln(x) value of KETO as function of
1/T (K).
Thermodynamic Parameter Assessment
It was required
to assess the thermodynamic terms (Gibbs free energy, enthalpy, and
entropy) for KETO in each solvent at the studied temperature. Generally,
up to now, explanation of thermodynamic function parameters (terms)
for the noted molecule was lacking in the literature. Therefore, these
functional parameters as validation tools for the experimental solubility
have been taken into consideration and there are the scarcity of quantitative
thermodynamics data for the drug in previous reports. In this study,
an attempt has been made to fill this gap for the assessment of the
solubility parameters. Fundamentally, a solution is said to be an
ideal solution when the change of entropy, volume, and energy on mixing
is null. Therefore, thermodynamic functional parameters of the solubilized
KETO in a particular solvent forming a non-ideal solution can be used
to characterize them, which are apparent standard dissolution enthalpy
(ΔsolH°), apparent standard
dissolution entropy (ΔsolS°),
and apparent standard Gibb free energy (ΔsolG°). These parameters were estimated through the apparent
thermodynamic analysis method for KETO in a particular organic solvent
over the explored temperature range. Moreover, the values of these
parameters (ΔsolH°, ΔsolG°, and ΔsolS°) were determined using the vanʼt Hoff and
Krug models.[33] It was required to estimate
the value of ΔsolH° for KETO
in an individual solvent at mean harmonic temperature (Thm = 305.0 K) using the vanʼt Hoff analysis model
(eq ).[29]where R and Thm are
the gas constant (8.314 J K–1 mol–1) and the mean harmonic temperature, respectively.
The enthalpy of dissolution (ΔsolH°) was calculated using the vanʼt Hoff plot. Moreover,
the value of ΔsolG° for KETO
was calculated using the Krug et al.[33] analysis
model (eq ) in each
organic solvent at Thm:The intercept value was estimated
from the vanʼt Hoff plot in each solvent (Figure ).Similarly, the ΔsolS° value of KETO was calculated using eq .[33]
GastroPlus Prediction Software: In Silico Study
The GastroPlus software (version
9.7, Simulation Plus, Inc., Lancaster,
USA) simulates in vitro data to in vivo performance using the ACAT (advanced compartmental absorption and
transit) model based on physiological-based oral absorption model
comprising nine compartmental segments of gastrointestinal tract (GIT).
The software estimates and predicts pharmacokinetic parameters using
PKPlus modules based on the input parameters. The program provides
three tabs (compound, physiological, and pharmacokinetics tabs) for
data input before analysis. There are several by-default parameters,
literature-based input values, and experimental data, which are processed
for simulation and prediction. The PSA module (parameter sensitivity
analysis) predicts the effect of physiochemical properties (solubility,
particle size, shape, density, pH, pKa, logP, etc.)
of the compound, the effect of the physiological condition (intestinal
transit time, volume, fast and fed condition), and effect of formulation
(nanoeffect, particle size, permeability coefficient) on PK parameters.In this study, a prediction study was carried out using experimental
data, ADMET predictor module-based suggested values, and literature
data. The permeation enhancer or solvent exhibiting maximum solubility
of KETO was used as a new construct and compared to pure KETO for
oral as well as transdermal delivery. The input parameters of the
drug are presented in Table obtained from various literature sources. For prediction
of transdermal performance, a new additional route module was used.
Statistical Analysis
All of the experiments were repeated
to get mean and standard deviation values. Data were statistically
analyzed using the Kruskal–Wallis analysis and Dennʼs
test. MINITAB (version 15.0, free trial version) was employed to run
nonlinear regression analysis using experimental values. The HSPiP
software (version 5.2.06) estimated the Hansen solubility parameters
of KETO and organic solvents. The value was considered significant
at p < 0.05 in the study.
Authors: Artem O Surov; Alexander P Voronin; Alex N Manin; Nikolay G Manin; Lyudmila G Kuzmina; Andrei V Churakov; German L Perlovich Journal: Mol Pharm Date: 2014-09-11 Impact factor: 4.939
Authors: Gerda A Jacobs; Minja Gerber; Maides M Malan; Jan L du Preez; Lizelle T Fox; Jeanetta du Plessis Journal: Drug Deliv Date: 2014-07-09 Impact factor: 6.419
Authors: Afzal Hussain; Mohammad A Altamimi; Obaid Afzal; Abdulmalik S A Altamimi; Abuzer Ali; Amena Ali; Fleming Martinez; Mohd Usman Mohd Siddique; William E Acree; Abolghasem Jouyban Journal: ACS Omega Date: 2022-01-02